Rhino-orbital mucormycosis following liver transplantation in a child with COVID-19 (a review of the literature and clinical observation)

Abstract

The incidence of mucormycosis, an opportunistic infection, has been increasing worldwide in recent years. This is primarily due to the spread of coronavirus disease 2019 and the increase in the number of at-risk populations. Risk groups include patients with conditions or diseases, such as diabetes, neutropenia, organ or stem cell transplantation (on immunosuppressive therapy), trauma and burns, hematological disorders, and steroid therapy. The basis of successful treatment includes early diagnosis based on the detection of the first nonspecific signs of the disease in patients at risk, rapid verification of pathogens, earliest possible start of etiotropic therapy, and prompt and aggressive surgical treatment (necrectomy). This study presents a clinical case of rhino-orbital mucormycosis in a child at risk. The patient had Alagille syndrome and was followed up from the age of 2 years. The syndrome is characterized by an insufficient number or the small diameter of the intrahepatic bile ducts that remove bile from the liver and lead to the development of liver cirrhosis. Liver transplantation is the only radical treatment method for liver cirrhosis in the absence of gross defects. By the age of 8 years, the syndrome led to liver cirrhosis, and in 2020, hepatectomy was performed, including orthotopic transplantation of a liver fragment from a related donor (aunt). The patient subsequently received immunosuppressive therapy. The article also described the changes in the clinic and imaging methods and stages of treatment by day. Clinical manifestations of mucormycosis appeared on day 6 of hospitalization, that is, edema of the left lower eyelid. The severe general condition of the child did not allow for early surgical treatment with the excision of necrotic tissues. Unfortunately, the patient died. Thus, possible errors in diagnosis and treatment were analyzed.

Keywords

rhino-orbital mucormycosis / eye orbit / liver transplantation / children

References

[1] Corneli OA, Alastruy-Izquierdo A, Arenz D, et al. Global guidelines for the diagnosis and treatment of mucormycosis: an initiative of the European Confederation for Medical Mycology in collaboration with the Mycoses Study Group. Lancet Infect Dis. 2019;19(12):e405–e421. doi: 10.1016/S1473-3099(19)30312-3

[2] Corneli O.A., Alastruy-Izquierdo A., Arenz D., et al. Global guidelines for the diagnosis and treatment of mucormycosis: an initiative of the European Confederation for Medical Mycology in collaboration with the Mycoses Study Group // Lancet Infect Dis. 2019. Vol. 19, N 12. Р. e405–e421. doi: 10.1016/S1473-3099(19)30312-3

[3] Dantas KS, Mauad T, de Andre CDS, et al. A single center retrospective study of the incidence of invasive fungal infections over 85 years of autopsy service in Brazil. Sci Rep. 2021;11(1):3943. doi: 10.1038/s41598-021-83587-1

[4] Dantas K.S., Mauad T., de Andre C.D.S., et al. A single center retrospective study of the incidence of invasive fungal infections over 85 years of autopsy service in Brazil // Sci Rep. 2021. Vol. 11, N 1. Р. 3943. doi: 10.1038/s41598-021-83587-1

[5] Sarvestani A, Pishdad G, Bolandparvaz S. Factors predisposing to mucormycosis in diabetic patients; 21 years experience in South Iran. Bull Emerge Trauma. 2013;1(4):164–170.

[6] Sarvestani A., Pishdad G., Bolandparvaz S. Factors predisposing to mucormycosis in diabetic patients; 21 years experience in South Iran // Bull Emerge Trauma. 2013. Vol. 1, N 4. Р. 164–170.

[7] Shariati A, Moradabadi A, Chegini Z, et al. An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies. Infect Drug Resist. 2020;13:2329–2354. doi: 10.2147/IDR.S254478

[8] Shariati A., Moradabadi A., Chegini Z., et al. An Overview of the Management of the Most Important Invasive Fungal Infections in Patients with Blood Malignancies // Infect Drug Resist. 2020. N 13. Р. 2329–2354. doi: 10.2147/IDR.S254478

[9] Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653. doi: 10.1086/432579

[10] Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases // Clin Infect Dis. 2005. Vol. 41, N 5. Р. 634–653. doi: 10.1086/432579

[11] Bitar D, Van Cauteren D, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15(9):1395–1401. doi: 10.3201/eid1509.090334

[12] Bitar D., Van Cauteren D., Lanternier F., et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006 // Emerg Infect Dis. 2009. Vol. 15, N 9. Р. 1395–1401. doi: 10.3201/eid1509.090334

[13] Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014;57 Suppl 3:85–90. doi: 10.1111/myc.12243

[14] Chakrabarti A., Singh R. Mucormycosis in India: unique features // Mycoses. 2014. Vol. 57, Suppl. 3. Р. 85–90. doi: 10.1111/myc.12243

[15] Ben-Ami R, Luna M, Lewis RE, et al. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect. 2009;59(2):134–138. doi: 10.1016/j.jinf.2009.06.002

[16] Ben-Ami R., Luna M., Lewis R.E., et al. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response // J Infect. 2009. Vol. 59, N 2. Р. 134–138. doi: 10.1016/j.jinf.2009.06.002

[17] Chamilos G, Lewis RE, Lamaris G, et al. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother. 2008;52(2):722–724. doi: 10.1128/AAC.01136-07

[18] Chamilos G., Lewis R.E., Lamaris G., et al. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage // Antimicrob Agents Chemother. 2008. Vol. 52, N 2. Р. 722–724. doi: 10.1128/AAC.01136-07

[19] Zelter PM, Surovcev EN, Kolsanov AV, et al. Radiology of rhinoorbitocerebral mycormycosis in patients after COVID-19. REJR. 2022;12(4):5–21. (In Russ). doi: 10.21569/2222-7415-2022-12-4-5-21

[20] Зельтер П.М., Суровцев Е.Н., Колсанов А.В., и др. Лучевая диагностика риноорбитоцеребрального мукормикоза у больных после COVID-19 // REJR. 2022. Т. 12, № 4. С. 5–21. doi: 10.21569/2222-7415-2022-12-4-5-21

[21] Karimov MB, Makhmadzoda ShK, Khaidarov ZB, Ziyozoda MR. COVID-19-associated rhino-orbital mucormycosis. Point of view. East-West. 2022;3:57–61. (In Russ). doi: 10.25276/2410-1257-2022-3-57-61

[22] Каримов М.Б., Махмадзола Ш.К., Хайдаров З.Б., Зиезода М.Р. COVID-19-ассоциированный риноорбитальный мукормикоз // Точка зрения. Восток-Запад. 2022. № 3. С. 57–61. doi: 10.25276/2410-1257-2022-3-57-61

[23] Kulagina LYu, Kurbanov AR. Cases of mucormycosis in the Kazan Republican Clinical Hospital. Chief Medical Officer. 2022;9:7–8. (In Russ). doi: 10.33920/med-03-2209-01

[24] Кулагина Л.Ю., Курбанов А.Р. Случаи заболеваний мукормикозом в республиканской клинической больнице города Казани // Главврач. 2022. № 9. С. 7–8. doi: 10.33920/med-03-2209-01

[25] Charushin AO, Khostelidi SN, Borovinsky RI, et al. The case of successful treatment of rhinoorbital mucormycosis in a COVID-19 patient in the perm region. Problems in Medical Mycology. 2022;24(3):13–19. (In Russ). doi: 10.24412/1999-6780-2022-3-13-19

[26] Чарушин А.О., Хостелиди С.Н., Боровинский Р.И., и др. Случай успешного лечения риноорбитального мукормикоза у больной COVID-19 в Пермском крае // Проблемы медицинской микологии. 2022. Т. 24, № 3. С. 13–19. doi: 10.24412/1999-6780-2022-3-13-19

[27] Kurysheva NI, Kim VYu, Plieva KhM, et al. Mukormikoz i ego glaznye proyavleniya: metodicheskoe posobie dlya praktikuyushchikh vrachei, meditsinskogo personala i ordinatorov. Moscow: GNTs RF – FMBTs im. A.I. Burnazyana; 2022. (In Russ).

[28] Курышева Н.И., Ким В.Ю., Плиева Х.М., и др. Мукормикоз и его глазные проявления: методическое пособие для практикующих врачей, медицинского персонала и ординаторов. Москва: ГНЦ РФ – ФМБЦ им. А.И. Бурназяна, 2022.

[29] Kolesnikov VN, Khanamirov AA, Boiko NV, et al. Postcovid sino-orbital mucormycosis: a case report. Bulletin of Otorhinolaryngology = Vestnik otorinolaringologii. 2022;87(3):107–111. (In Russ). doi: 10.17116/otorino202287031107

[30] Колесников В.Н., Ханамиров А.А., Бойко Н.В., и др. Случай постковидного синоорбитального мукормикоза // Вестник оториноларингологии. 2022. Т. 87, № 3. С. 107–111. doi: 10.17116/otorino202287031107

[31] Kurysheva NI. COVID-19 i porazheniya organa zreniya. Moscow: LARGO; 2021. (In Russ).

[32] Курышева Н.И. COVID-19 и поражения органа зрения. Москва: ЛАРГО, 2021.

[33] Sundaram N, Bhende T, Yashwant R, et al. Mucormycosis in COVID-19 patients. Indian J Ophthalmol. 2021;69(12):3728–3733. doi: 10.4103/ijo.IJO_1316_21

[34] Sundaram N., Bhende T., Yashwant R., et al. Mucormycosis in COVID-19 patients // Indian J Ophthalmol. 2021. Vol. 69, N 12. Р. 3728–3733. doi: 10.4103/ijo.IJO_1316_21

[35] Pana ZD, Seidel D, Skiada A, et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016;6(1):667. doi: 10.1186/s12879-016-2005-1

[36] Pana Z.D., Seidel D., Skiada A., et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries // BMC Infect Dis. 2016. Vol. 6, N 1. Р. 667. doi: 10.1186/s12879-016-2005-1

[37] Mahalaxmi I, Jayaramaya K, Venkatesan D, et al. Mucormycosis: an opportunistic pathogen during COVID-19. Environ Res. 2021;201:111643. doi: 10.1016/j.envres.2021.111643

[38] Mahalaxmi I., Jayaramaya K., Venkatesan D., et al. Mucormycosis: an opportunistic pathogen during COVID-19 // Environ Res. 2021. N 201. Р. 111643. doi: 10.1016/j.envres.2021.111643

[39] Gebremariam T, Liu M, Luo G, et al. CotH3 mediates fungal invasion of host cells during mucormycosi. J Clin Invest. 2014;124(1):237–250. doi: 10.1172/JCI71349

[40] Gebremariam T., Liu M., Luo G., et al. CotH3 mediates fungal invasion of host cells during mucormycosi // J Clin Invest. 2014. Vol. 124, N 1. Р. 237–250. doi: 10.1172/JCI71349

[41] Roilides E, Antachopoulos C, Simitsopoulou M. Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs. Mycoses. 2014;57 Suppl 3:40–47. doi: 10.1111/myc.12236

[42] Roilides E., Antachopoulos C., Simitsopoulou M. Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs // Mycoses. 2014. Vol. 57, Suppl. 3. Р. 40–47. doi: 10.1111/myc.12236

[43] Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653. doi: 10.1086/432579

[44] Knudsen T.A., Sarkisova T.A., Schaufele R.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases // Clin Infect Dis. 2005. Vol. 41, N 5. Р. 634–653. doi: 10.1086/432579

[45] Ruhnke M, Groll AH, Mayser P, et al. University of Manchester in association with the LIFE program. Estimated burden of fungal infections in Germany. Mycoses. 2015;58 Suppl 5:22–28. doi: 10.1111/myc.12392

[46] Ruhnke M., Groll A.H., Mayser P., et al. University of Manchester in association with the LIFE program. Estimated burden of fungal infections in Germany // Mycoses. 2015. Vol. 58, Suppl. 5. Р. 22–28. doi: 10.1111/myc.12392

[47] Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–445. doi: 10.1128/CMR.00056-10

[48] Gomes M.Z., Lewis R.E., Kontoyiannis D.P. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species // Clin Microbiol Rev. 2011. Vol. 24, N 2. Р. 411–445. doi: 10.1128/CMR.00056-10

[49] Jeong W, Keighley C, Wolfe R, et al. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. Int J Antimicrob Agents. 2019;53(5):589–597. doi: 10.1016/j.ijantimicag.2019.01.002

[50] Jeong W., Keighley C., Wolfe R., et al. Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports // Int J Antimicrob Agents. 2019. Vol. 53, N 5. Р. 589–597. doi: 10.1016/j.ijantimicag.2019.01.002

[51] Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54 Suppl 1:55–60. doi: 10.1093/cid/cir868

[52] Walsh T.J., Gamaletsou M.N., McGinnis M.R., et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis) // Clin Infect Dis. 2012. Vol. 54, Suppl. 1. Р. 55–60. doi: 10.1093/cid/cir868

[53] Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–509. doi: 10.1086/590004

[54] Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis // Clin Infect Dis. 2008. Vol. 47, N 4. Р. 503–509. doi: 10.1086/590004

[55] Bae MS, Kim EJ, Lee KM, Choi WS. Rapidly Progressive Rhino-orbito-cerebral Mucormycosis Complicated with Unilateral Internal Carotid Artery Occlusion: A Case Report. Neurointervention. 2012;7(1):45–49. doi: 10.5469/neuroint.2012.7.1.45

[56] Bae M.S., Kim E.J., Lee K.M., Choi W.S. Rapidly Progressive Rhino-orbito-cerebral Mucormycosis Complicated with Unilateral Internal Carotid Artery Occlusion: A Case Report // Neurointervention. 2012. Vol. 7, N 1. Р. 45–49. doi: 10.5469/neuroint.2012.7.1.45

[57] Vallverdú Vidal M, Iglesias Moles S, Palomar Martínez M. Rhino-orbital-cerebral mucormycosis in a critically ill patient. Med Intensiva. 2017;41(8):509–510. doi: 10.1016/j.medin.2016.03.001

[58] Vallverdú Vidal M., Iglesias Moles S., Palomar Martínez M. Rhino-orbital-cerebral mucormycosis in a critically ill patient // Med Intensiva. 2017. Vol. 41, N 8. Р. 509–510. doi: 10.1016/j.medin.2016.03.001

[59] Bhansali A, Bhadada S, Sharma A, et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J. 2004;80(949):670–674. doi: 10.1136/pgmj.2003.016030

[60] Bhansali A., Bhadada S., Sharma A., et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes // Postgrad Med J. 2004. Vol. 80, N 949. Р. 670–674. doi: 10.1136/pgmj.2003.016030

[61] Goh LC, Shakri ED, Ong HY, et al. A seven-year retrospective analysis of the clinicopathological and mycological manifestations of fungal rhinosinusitis in a single-centre tropical climate hospital. J Laryngol Otol. 2017;131(9):813–816. doi: 10.1017/S0022215117001505

[62] Goh L.C., Shakri E.D., Ong H.Y., et al. A seven-year retrospective analysis of the clinicopathological and mycological manifestations of fungal rhinosinusitis in a single-centre tropical climate hospital // J Laryngol Otol. 2017. Vol. 131, N 9. Р. 813–816. doi: 10.1017/S0022215117001505

[63] Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS One. 2017;12(6):e0179136. doi: 10.1371/journal.pone.0179136

[64] Guinea J., Escribano P., Vena A., et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates // PLoS One. 2017. Vol. 12, N 6. Р. e0179136. doi: 10.1371/journal.pone.0179136

[65] Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837. doi: 10.1016/S1473-3099(16)00071-2

[66] Marty F.M., Ostrosky-Zeichner L., Cornely O.A., et al. VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis // Lancet Infect Dis. 2016. Vol. 16, N 7. Р. 828–837. doi: 10.1016/S1473-3099(16)00071-2

[67] Shoham S, Magill SS, Merz WG, et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol. 2010;48(3):511–517. doi: 10.3109/13693780903311944

[68] Shoham S., Magill S.S., Merz W.G., et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases // Med Mycol. 2010. Vol. 48, N 3. Р. 511–517. doi: 10.3109/13693780903311944

[69] Legrand M, Gits-Muselli M, Boutin L, et al. Detection of Circulating Mucorales DNA in Critically Ill Burn Patients: Preliminary Report of a Screening Strategy for Early Diagnosis and Treatment. Clin Infect Dis. 2016;63(10):1312–1317. doi: 10.1093/cid/ciw563

[70] Legrand M., Gits-Muselli M., Boutin L., et al. Detection of Circulating Mucorales DNA in Critically Ill Burn Patients: Preliminary Report of a Screening Strategy for Early Diagnosis and Treatment // Clin Infect Dis. 2016. Vol. 63, N 10. Р. 1312–1317. doi: 10.1093/cid/ciw563

[71] Hong HL, Lee YM, Kim T, et al. Risk factors for mortality in patients with invasive mucormycosis. Infect Chemother. 2013;45(3):292–298. doi: 10.3947/ic.2013.45.3.292

[72] Hong H.L., Lee Y.M., Kim T., et al. Risk factors for mortality in patients with invasive mucormycosis // Infect Chemother. 2013. Vol. 45, N 3. Р. 292–298. doi: 10.3947/ic.2013.45.3.292

[73] Palejwala SK, Zangeneh TT, Goldstein SA, Lemole GM. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis. Surg Neurol Int. 2016;7:61. doi: 10.4103/2152-7806.182964

[74] Palejwala S.K., Zangeneh T.T., Goldstein S.A., Lemole G.M. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis // Surg Neurol Int. 2016. N 7. Р. 61. doi: 10.4103/2152-7806.182964

[75] Walsh TJ, Skiada A, Cornely OA, et al. Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses. 2014;57 Suppl 3(0 3):2–7. doi: 10.1111/myc.12249

[76] Walsh T.J., Skiada A., Cornely O.A., et al. Development of new strategies for early diagnosis of mucormycosis from bench to bedside // Mycoses. 2014. Vol. 57, Suppl. 3, 0 3. P. 2–7. doi: 10.1111/myc.12249

[77] Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444. doi: 10.3324/haematol.2016.152900

[78] Tissot F., Agrawal S., Pagano L., et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients // Haematologica. 2017. Vol. 102, N 3. Р. 433–444. doi: 10.3324/haematol.2016.152900

[79] Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56 Suppl_1:93–101. doi: 10.1093/mmy/myx101

[80] Skiada A., Lass-Floerl C., Klimko N., et al. Challenges in the diagnosis and treatment of mucormycosis // Med Mycol. 2018. Vol. 56, Suppl. 1. Р. 93–101. doi: 10.1093/mmy/myx101

[81] Pal R, Singh B, Bhadada SK, et al. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses. 2021;64(12):1452–1459. doi: 10.1111/myc.13338

[82] Pal R., Singh B., Bhadada S.K., et al. COVID-19-associated mucormycosis: An updated systematic review of literature // Mycoses. 2021. Vol. 64, N 12. Р. 1452–1459. doi: 10.1111/myc.13338

RIGHTS & PERMISSIONS

Eco-Vector